Geneva, June 4 -- International Clinical Trials Registry received information related to the study (ISRCTN70607799) titled 'A study in healthy volunteers to look at safety and tolerability of ALKS 4510' on May 20.
Study Type: Interventional
Study Design:
Single-centre randomized double-blind placebo-controlled study (Safety)
Primary Sponsor: Alkermes (United States)
Condition:
Phase 1 study drug
Other
Intervention:
Part 1 SAD: Healthy volunteers will be randomized by using a randomization code to receive a single dose of oral ALKS 4510 or placebo for 1 day in each of five cohorts
Part 2 MAD: Healthy volunteers will be randomized by using a randomization code to receive one dose of oral ALKS 4510 or placebo every day for 10 conse...